• Use of mifepristone for preoperative preparation of reproductive age women with uterine leiomyoma

Use of mifepristone for preoperative preparation of reproductive age women with uterine leiomyoma

HEALTH OF WOMAN. 2017.4(120):107–110; doi 10.15574/HW.2017.120.107

Kornatska А., Chubei G., Flaksemberg M.
SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev

The objective: was to evaluate the possibility of using mifepristone (Gynestril) as a hormonal preparation for conservative myomectomy.

Patients and methods. The effect of a three-month course of mifepristone (Gynestril) at a dose of 50 mg per day on the dynamics of clinical indicators, ultrasound, the results of surgical treatment in 30 women of reproductive age with uterine leiomyoma was studied.

Results. The use of an antigestagenic drug for preoperative preparation led to a decrease in the incidence of pain syndrome, dysfunction of the pelvic organs in most patients. The presence of amenorrhea in 90% of women contributed to the normalization of hemoglobin. The positive dynamics of the mioma nodes sizes and the uterus made it possible to reduce the time of operative intervention and the volume of intraoperative blood loss.

Conclusion. The use of antigestagen preparations, in particular mifepristone (Gynestril), for the purpose of preoperative preparation, allows obtaining the most positive result of organ-preserving treatment of uterine myoma in reproductive age women.

Key words: leiomyoma of the uterus, reproductive age, preoperative preparation, mifepristone, Gynestril.

REFERENCES

1. Gritsenko YaV, Konstantinova OD, Cherkasov SV. 2012. Mioma matki v sovremennom mire: aktualnyie voprosyi patogeneza, diagnostiki i lecheniya. Byulleten Orenburgskogo nauchnogo tsentra UrO RAN (elektronnyiy zhurnal) 3:23.

2. Kornatska AH, Vovk IB, Ivaniuta LI, Chubei HV. 2009. Suchasni pidkhody do kompleksnoho likuvannia leiomiomy matky v poiednanni z adenomiozom u zhinok z nerealizovanoiu reproduktyvnoiu funktsiieiu. Problemы, dostyzhenyia y perspektyvы razvytyia medyko-byolohycheskykh nauk y praktycheskoho zdravookhranenyia. Trudы Krуmskoho hosudarstvennoho unyversyteta ym. S.Y. Heorhyevskoho 145;III:43–45.

3. Ozolinya LA, Ignatchenko OYu, Lapina IA, Dergacheva IA. 2009. Vozmozhnosti gormonalnoy terapii v lechenii miomyi matki. «Vestnik RGMU» 4:20–23.

4. Buyanova SN, Yudina NV, Gukasyan SA, Sheina EN. 2015. Taktika vedeniya patsientok s miomoy matki ot rannego reproduktivnogo do postmenopauzalnogo vozrasta. RMZh 1:3–5.

5. Zvyichaynyiy MA, Vorontsova AV, Chilova AL, Fedotovskih IV. 2014. Giperplasticheskiy sindrom reproduktivnoy sistemyi u zhenschin v perimenopauze: taktika konservativnoy terapii i reabilitatsii. Ginekologiya 1:44–48.

6. Donnez J, Vazquez F, Tomaszewski J et al. 2014. PEARL III and PEARL III Extension Study Group. Longterm treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 101(6):1565–1573. https://doi.org/10.1016/j.fertnstert.2014.02.008; PMid:24630081

7. Tristan M, Orozco LJ, Steed A et al. 2012. Mifepristone for uterine fibroids. Cochrane Database Syst. Rev. Issue 8:CD007687. https://doi.org/10.1002/14651858.CD007687.pub2